D-enantiomeric Peptides for Anti-Inflammatory Treatment of Amyotropic Lateral Sclerosis (als) and Other Diseases Driven by Neuro-inflammation

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention relates to new polymers composed of D-enantiomeric peptides, specifically sequences like SEQ ID NO: 1 or their close homologues, for use in anti-inflammatory treatment of Amyotrophic Lateral Sclerosis (ALS) and other diseases driven by neuro-inflammation. The polymers, especially dimers (two-unit chains) made entirely of D-amino acids, have shown to delay onset and progression of ALS in animal models by reducing neuroinflammation, addressing an urgent medical need where current therapies are limited.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of Amyotrophic Lateral Sclerosis (ALS) to slow disease progression.
• Therapy for other neurodegenerative diseases involving neuro-inflammation, such as multiple sclerosis or Parkinson's disease.
• Development of anti-inflammatory pharmaceuticals for central nervous system disorders.
• Potential use in research to study neuro-inflammation pathways and test new therapeutic strategies.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a novel therapeutic mechanism for ALS targeting neuro-inflammation rather than traditional pathways (like COX inhibition).
• Potential to slow the onset and progression of ALS, thereby improving patient survival and quality of life.
• The use of D-enantiomeric amino acids offers greater stability and resistance to breakdown by natural enzymes, potentially increasing effectiveness and duration.
• May be tailored or linked to other molecules to improve solubility, absorption, or for targeted delivery across the blood-brain barrier.
• Offers an alternative to current treatments, which only modestly extend ALS patient survival.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to a polymer comprising at least one monomer, wherein the at least one monomer comprises a peptide having an amino acid sequence selected from the group comprising SEQ ID NO: 1 or homologues having an identity of at least 80% thereof, and to a pharmaceutical composition comprising such a peptide for use in the treatment of amyotrophic lateral sclerosis (ALS).